It is estimated that 350 million people worldwide use biologics on a regular basis to treat their medical conditions. These therapies are incredibly innovative and have expanded the arsenal of effective treatment options for cancer, rheumatoid arthritis, and other serious illnesses. However, the high costs of these therapies, although understandable, can create access issues for patients. That is why biosimilars are so important. Read Article ›
The November 2016 presidential elections have cast a shadow in many minds about the future of the transition from the volume-driven, fee-for-service healthcare delivery model to the value-based care model. With the current promises of repealing and replacing the Affordable Care Act (ACA) of 2010, physicians and healthcare providers are left guessing as to what they will be expected to do, and where their future is heading. Read Article ›
